Mr. Ledger has been responsible for leading Miravo through its evolution from a manufacturing focused business, to a diversified, global pharmaceutical company. Mr. Ledger joined Miravo in April 2016 as Vice President, Business Development, was appointed President of Miravo in November 2016, and subsequently became President & CEO in November 2017.
Mr. Ledger has over 16 years experience in building product portfolios and pharmaceutical businesses with Canadian, U.S. and international transactional experience. Prior to joining Nuvo, he served as Vice President, Business Development & International Business at Tribute Pharmaceuticals Canada Inc. While at Tribute, Mr. Ledger was a member of the senior management team that completed six transactions with an aggregate value of over CDN$250 million, culminating in a merger with Pozen Inc. and the subsequent formation of Aralez Pharmaceuticals Inc. Prior to joining Tribute, Mr. Ledger was Director, Business Development at SteriMax Inc., a specialty pharmaceutical company focused on the commercialization of essential hospital and retail pharmacy products within Canada, where Mr. Ledger was responsible for a series of successful product acquisition and licensing transactions.
Mr. Ledger holds an honours Bachelor of Business Administration degree from Trent University and is an active member of the Canadian Healthcare Licensing Association (CHLA).
Ms. Burkett joined Miravo in 2012 and was promoted to CFO in September 2016. As CFO, Ms. Burkett’s transactional experience includes mergers and acquisitions, corporate restructuring and reorganization and financing arrangements. Ms. Burkett’s executive leadership responsibilities include Miravo’s financial operations, human resources and information technology functions.
Prior to her CFO role, Ms. Burkett held a number of finance roles with increasing responsibilities with Miravo, most recently as Corporate Controller, where she was instrumental in the carve-out of Crescita Therapeutics Inc., created on March 1, 2016 by way of a plan of arrangement that reorganized Nuvo Research Inc. into Miravo and Crescita.
Prior to joining Miravo, Ms. Burkett worked for PwC performing audit, internal audit and consulting work for its clients.
Ms. Burkett is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration degree from the Ivey Business School at the University of Western Ontario.
Ms. Demerino brings over 20 years of finance and operations experience at public companies to Miravo. Ms. Demerino began her career as an audit manager at PwC and has extensive experience across multiple industries in addition to the life science sector, including financial services and clean technology.
Ms. Demerino received her bachelor’s degree in Commerce from Mount Allison University, is a Chartered Professional Accountant and holds the Certified Internal Auditor designation.
Mr. Berardelli has more than 30 years of experience in sales, marketing, strategic brand planning and commercial excellence. He has held numerous senior positions in the pharmaceutical industry working extensively in sales, marketing, continuing education and wholesale and trade relations. Mr. Berardelli has worked for a number of large and start-up pharmaceutical companies, in addition to Miravo, including, Rhone-Poulenc Rorer, Biovail Pharmaceuticals Canada, Genzyme and Tribute Pharmaceuticals. He has led and been involved in several product launches in Cardiology, Pain, Allergy, Dermatology, Neurology, and Oncology. He has managed large product portfolios in the prescription, device and OTC/BTC space.
Dr. Chiasson has 25 years of experience in pharmaceuticals and biotechnology. He has held positions of increasing responsibility in Research and Development and executive management.
During his time in industry, he has worked on several small molecules, biologics and biotechnology products at various stages of product development, including the final registration phase in Canada, the U.S. and Europe. He has held positions of increasing responsibility during his career with Novartis, Draxis Health, Bayer Biologics, Amgen, Optum and Tribute Pharmaceuticals Inc. (Tribute). Most recently, he was Chief Scientific Officer at Tribute and part of the executive team that grew the company to a final merger that saw a rise of approximately ten times in market capitalization during his tenure. Prior to Tribute, he was Vice President of US Strategic Regulatory Affairs and Global Medical Services at Optum where he was responsible for a team of scientists and physicians supporting client drug development, safety and regulatory strategies and operations.
Dr. Chiasson is a trained neuroscientist and pharmacologist and received a BSc (hons), MSc. (Physiology and Biophysics) and PhD (Neuroscience and Pharmacology) from Dalhousie University and conducted his Post-Doctoral studies at the University of Toronto.
Ms. Loucaides has extensive legal and business experience in the biotechnology and pharmaceutical industry. In her role at Miravo, she is responsible for a wide range of legal and regulatory areas, including intellectual property, licensing, acquisitions, litigation, regulatory law and compliance. Prior to joining Nuvo in 2008, Ms. Loucaides was an associate lawyer with Bereskin & Parr in Toronto. As a member of the firm’s biotechnology and pharmaceutical practice group, she advised clients on patents, licensing and litigation matters.
Ms. Loucaides is a graduate of Osgoode Hall Law School and holds a Bachelor degree and a Master of Science degree from the University of Toronto. She was awarded a Canada Scholarship for Science and Technology and a scholarship from the Medical Research Counsel. She is a registered Patent Agent in Canada and the United States, and has a Chartered Director (C.Dir.) designation.